Tumor-Derived Extracellular Vesicles Combining ALOX15 and RSL3 Enhance Lipid Oxidation and Antitumor Activity
Open Access
- 23 October 2026
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (11) , 1357
Abstract
Background/Objectives: Enhancing lipid peroxide formation while impairing antioxidant defenses represents a promising strategy for ferroptosis-based cancer therapy. This study aimed to evaluate a tumor-derived extracellular vesicle (EV) formulation combining ALOX15-associated lipid oxidation with RSL3-mediated inhibition of GPX4. Methods: RSL3@ALOX15-MPs were prepared by associating the GPX4 inhibitor RSL3 with ALOX15-containing EVs derived from 4T1 tumor cells. The formulation was characterized, and its effects on lipid oxidation, cell viability, and ferroptosis-associated responses were evaluated in vitro. Antitumor efficacy, biodistribution, tumor immune-cell phenotypes, and preliminary tolerability were assessed in 4T1 tumor-bearing mice. Results: The formulation exhibited EV-associated characteristics and an RSL3 loading content of approximately 3.8% relative to MP protein mass. In 4T1 cells, RSL3@ALOX15-MPs increased BODIPY-C11 oxidation to approximately five times the PBS control level and reduced cell viability to approximately 30%, compared with approximately 60% following RSL3-MP treatment. Ferrostatin-1, liproxstatin-1, and deferoxamine partially rescued cell viability and attenuated lipid oxidation. RSL3-containing formulations reduced total glutathione peroxidase activity, while ALOX15 inhibition attenuated lipid oxidation and cytotoxicity. The combined formulation also resulted in lower cell viability than a physical mixture of the individual formulations. In vivo, RSL3@ALOX15-MPs increased tumor RSL3 accumulation, altered intratumoral immune-cell phenotypes and cytokine levels, inhibited tumor growth, and prolonged survival. Conclusions: Combining ALOX15-associated lipid oxidation with RSL3 delivery using tumor-derived EVs enhanced ferroptosis-associated cytotoxicity in vitro and demonstrated antitumor efficacy in the 4T1 tumor model. Further studies are required to establish GPX4-specific effects and the causal contributions of ferroptosis and immune responses to the in vivo therapeutic outcomes.Keywords
Funding Information
- National Natural Science Foundation of China (52503383)
- National Natural Science Foundation of China (32401168)
- National Natural Science Foundation of China (82503644)
- Jiangsu Provincial Natural Science Foundation Youth Science Fund (BK20240790)
- Hainan University (XJ2600001772)
- Suzhou Science and Technology Program (SYWD2025018)
This publication has 25 references indexed in Scilit:
- Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approachesJournal of Extracellular Vesicles, 2024
- PPARG-mediated ferroptosis in dendritic cells limits antitumor immunityBiochemical and Biophysical Research Communications, 2021
- Tumor‐derived microparticles in tumor immunology and immunotherapyEuropean Journal of Immunology, 2020
- Role of Mitochondria in FerroptosisMolecular Cell, 2019
- Ferroptosis: A Regulated Cell Death Nexus Linking Metabolism, Redox Biology, and DiseaseCell, 2017
- Macrophage Activation and Polarization: Nomenclature and Experimental GuidelinesImmunity, 2014
- Regulation of Ferroptotic Cancer Cell Death by GPX4Cell, 2014
- Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell DeathCell, 2012
- Synthetic Lethal Screening Identifies Compounds Activating Iron-Dependent, Nonapoptotic Cell Death in Oncogenic-RAS-Harboring Cancer CellsChemistry & Biology, 2008
- 8-Hydroxy-2′-deoxyguanosine as a marker of oxidative DNA damage related to occupational and environmental exposuresInternational Archives of Occupational and Environmental Health, 2006